I think the answer to that question is complex. There are multiple possible answers, from supply chains to the fact that it is a revolutionary technology. As I mentioned in my comments, the technology we're using for most of the current vaccines didn't even exist a few years ago, etc.
I will, by the way, call on my colleague, Mr. Hamill, to jump in. His expertise is on the IP side of things as well.
Again, my quick response to you would be that there are multiple reasons for it. This is why we are pushing to make sure we don't move too quickly to any one solution that is nice and shiny on the outside but will not have the intended effect in terms of the goals of this particular committee.
Declan, did you want to add any comments?